Obesity as a Risk Factor of Severe Outcome of COVID-19: A Pair-Matched 1:2 Case-Control Study.
COVID-19
SARS-CoV-2 infection
mortality
obesity
severity of disease
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Jun 2023
15 Jun 2023
Historique:
received:
22
04
2023
revised:
07
06
2023
accepted:
13
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
The nature of the association between obesity and poor prognosis of COVID-19 without the evaluation of other co-pathologies associated has not yet been clearly evaluated. The aim of the present pair-matched case-control study was to investigate the outcome of patients with SARS-CoV-2 infection in obese and non-obese patients matched considering gender, age, number of comorbidities, and Charlson Comorbidity Index. All the adults hospitalized for SARS-CoV-2 infection and with BMI ≥ 30 kg/m Of the 1282 patients with SARS-CoV-2 infection followed during the study period, 141 patients with obesity and 282 patients without were enrolled in the case and control groups, respectively. Considering matching variables, there was no statistical difference between the two groups. Patients in the Control group developed more frequently a mild-moderate disease (67% vs. 46.1%, respectively), whereas obese patients were more prone to need intensive care treatment (41.8% vs. 26.6%, respectively; We confirmed an association between obesity and severe outcome of patients with COVID-19, also considering other factors associated with a severe outcome of COVID-19. Thus, in the case of SARS-CoV-2 infection, the subjects with BMI ≥ 30 kg/m
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The nature of the association between obesity and poor prognosis of COVID-19 without the evaluation of other co-pathologies associated has not yet been clearly evaluated. The aim of the present pair-matched case-control study was to investigate the outcome of patients with SARS-CoV-2 infection in obese and non-obese patients matched considering gender, age, number of comorbidities, and Charlson Comorbidity Index.
METHODS
METHODS
All the adults hospitalized for SARS-CoV-2 infection and with BMI ≥ 30 kg/m
RESULTS
RESULTS
Of the 1282 patients with SARS-CoV-2 infection followed during the study period, 141 patients with obesity and 282 patients without were enrolled in the case and control groups, respectively. Considering matching variables, there was no statistical difference between the two groups. Patients in the Control group developed more frequently a mild-moderate disease (67% vs. 46.1%, respectively), whereas obese patients were more prone to need intensive care treatment (41.8% vs. 26.6%, respectively;
DISCUSSION
CONCLUSIONS
We confirmed an association between obesity and severe outcome of patients with COVID-19, also considering other factors associated with a severe outcome of COVID-19. Thus, in the case of SARS-CoV-2 infection, the subjects with BMI ≥ 30 kg/m
Identifiants
pubmed: 37373748
pii: jcm12124055
doi: 10.3390/jcm12124055
pmc: PMC10298877
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Regione Campania
ID : POR 2019
Références
Int J Environ Res Public Health. 2022 Nov 30;19(23):
pubmed: 36498078
J Infect Public Health. 2023 Jan;16(1):136-142
pubmed: 36521329
J Gastrointestin Liver Dis. 2021 Jun 18;30(2):274-282
pubmed: 33951119
Heliyon. 2020 Aug;6(8):e04696
pubmed: 32844126
Eur J Health Econ. 2022 Mar;23(2):177-192
pubmed: 34347176
Front Oncol. 2021 May 07;11:662746
pubmed: 34026639
Circulation. 2021 May 25;143(21):e984-e1010
pubmed: 33882682
Infez Med. 2022 Dec 1;30(4):539-546
pubmed: 36482947
Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85
pubmed: 27356115
Int J Environ Res Public Health. 2020 Jul 14;17(14):
pubmed: 32674450
Crit Care. 2019 Jul 19;23(1):258
pubmed: 31324202
Eur J Intern Med. 2023 Feb;108:28-36
pubmed: 36411156
Metabolism. 2021 Jan;114:154408
pubmed: 33080269
Diabetes Metab Res Rev. 2021 Feb;37(2):e3377
pubmed: 32588943
Pathogens. 2022 Jun 06;11(6):
pubmed: 35745506
J Mol Med (Berl). 2021 Jul;99(7):899-915
pubmed: 33824998
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Front Aging Neurosci. 2021 Jun 29;13:698184
pubmed: 34267649
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Eur J Prev Cardiol. 2022 Dec 7;29(17):2218-2237
pubmed: 36007112
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Healthcare (Basel). 2023 Mar 21;11(6):
pubmed: 36981559
Ann Intern Med. 2020 Nov 17;173(10):773-781
pubmed: 32783686